# Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

> **NCT04253145** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fundacion Oncosur** · enrollment: 184 (estimated)

## Conditions studied

- Carcinoma, Small Cell Lung

## Interventions

- **DRUG:** PM 01183
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04253145
- **Lead sponsor:** Fundacion Oncosur
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-13
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04253145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04253145, "Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04253145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*